Dr. Halfdanarson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511Fax+1 507-284-1803
Summary
- Medical Oncologist with a focus on neuroendocrine and GI oncology.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003 - 2007
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2000 - 2003
University of IcelandClass of 1995
Certifications & Licensure
AZ State Medical License 2012 - 2025
MN State Medical License 2015 - 2025
IA State Medical License 2000 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Feb 01
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2014 Jan 01
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Start of enrollment: 2016 Aug 16
Publications & Presentations
PubMed
- Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma.Shruti Chandra, Thorvardur R Halfdanarson, Erin E Carlson, Kari G Rabe, Amit Mahipal
Endocrine-Related Cancer. 2025-04-01 - Fruquintinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Multiply Metastatic Rectal Cancer.Caroline B Ledet, Ugur Sener, Derek R Johnson, Kimberly Ku, Thorvardur R Halfdanarson
Clinical Colorectal Cancer. 2025-03-01 - Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tu...Hallbera Gudmundsdottir, Rondell P Graham, Patricia T Greipp, Elizabeth B Habermann, Ryan A Knudson
Journal of Neuroendocrinology. 2025-02-13
Authored Content
- Borderline Resectable and Locally Advanced Pancreas Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Neoadjuvant Therapy Pathologic Response and Prediction of SurvivalOctober 2020
Press Mentions
Sharing Mayo Clinic: Georgia Man with Neuroendocrine Cancer Gains Quality of Life Thanks to New Nuclear Med TherapyApril 17th, 2022- Georgia Man with Neuroendocrine Cancer Gains Quality of Life Thanks to New Nuclear Med TherapyApril 14th, 2022
- Hyperammonemic Encephalopathy in a Patient with Fibrolamellar Hepatocellular Carcinoma: Case Report and Literature ReviewJanuary 28th, 2019
Professional Memberships
- Member
- Member
- Member
- North American Neuroendocrine Tumor Society (NANETS)Member
- European Neuroendocrine Tumor Society (ENETS)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
